Posters
Vector analysis of astigmatic changes and optical quality outcomes after wavefront-guided laser in situ keratomileusis using a high resolution aberrometer
Poster Details
First Author: J.Durán SPAIN
Co Author(s): E. Gutierrez R. Atienza A. Monje D. Pinero
Abstract Details
Purpose:
To investigate the ocular optical quality results as well as the astigmatic changes evaluated by vector analysis of wavefront-guided (WFG) laser in situ keratomileusis (LASIK) in low to moderate myopic eyes with different levels of astigmatism
Setting:
Instituto Cl�Ã�nico-Quir�Ã�ºrgico de Oftalmolog�Ã�a (ICQO), Bilbao, Vizcaya, Spain
Methods:
Prospective consecutive clinical trial. 33 eyes undergoing WFG LASIK with the STAR S4IR excimer laser combined with the iDesign system for treatment calculation (Abbott Medical Optics) were enrolled in the study. Changes in visual acuity, refraction, high order aberrations and ocular scattering index (OSI) were evaluated during a 3-month follow-up. Likewise, the Alpins method was used to analyze the astigmatic changes
Results:
A significant reduction was observed in sphere and cylinder (p<0.001), with significant improvement associated in uncorrected (UDVA) and corrected distance visual acuity (CDVA) (p<0.001). All eyes had a spherical equivalent within �Â�±0.50 D three months after surgery. A total of 27.3% of eyes gained lines of CDVA. No significant changes were observed in primary coma and spherical aberration (p�â��¥0.551). No significant changes were observed in OSI (p=0.36). Significant increase in the magnitude of error (p=0.007) and significant decrease in the correction index (p=0.004) were observed during the follow-up, with mean 90-day postoperative values of 0.24�Â�±0.28 D and 0.86�Â�±0.17, respectively.
Conclusions:
WFG LASIK using a high resolution aberrometer provides a safe and efficacious correction of myopic astigmatism, with preservation of the ocular optical quality.
Financial Disclosure:
research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company
